Emergence of Hybrid Models of Genetic Testing Beyond Direct-to-Consumer or Traditional Labs
- PMID: 31145414
- PMCID: PMC6684382
- DOI: 10.1001/jama.2019.5670
Emergence of Hybrid Models of Genetic Testing Beyond Direct-to-Consumer or Traditional Labs
Conflict of interest statement
Conflicts of Interest Disclosures:
Dr. Phillips receives consulting income from Illumina, Inc and previously received consulting income from Counsyl, Inc (now Myriad Women’s Health). Dr. Trosman previously received consulting income from Counsyl, Inc (now Myriad Women’s Health). Mr. Douglas receives consulting income from Illumina, Inc.
References
-
- Gill J, Obley AJ, Prasad V. Direct-to-Consumer Genetic Testing: The Implications of the US FDA’s First Marketing Authorization for BRCA Mutation Testing. JAMA. 2018;319(23):2377–2378. - PubMed
-
- Invitae Annual Report - United States Securities and Exchange Commission Form 10-K. 2019; http://d18rn0p25nwr6d.cloudfront.net/CIK-0001501134/303998a9-82bc-4c5c-b.... Accessed March 25, 2019.
-
- National Institutes of Health Genetic Testing Registry. 2019; https://www.ncbi.nlm.nih.gov/gtr/. Accessed March 26, 2019.
-
- Myriad Genetics Annual Corporate Presentation - January 7, 2019. 2019; http://investor.myriad.com/static-files/fbced189-f3dd-431b-b22d-8ae57cad.... Accessed March 25, 2019.
